QDEL Stock Analysis: Quidel | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 1.189m USD | 12M Return: -42.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 24.5M
Qual. Beats: 0
Rev. Trend: -93.5%
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
QuidelOrtho Corporation (NASDAQ: QDEL) is a San Diego-based diagnostic testing company that operates through four business units: Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics. Its Labs unit provides clinical chemistry and immunoassay instruments and tests used in clinical laboratories to measure chemicals, proteins, antibodies, and disease markers in bodily fluids. The Transfusion Medicine unit supplies immunohematology instruments for blood typing and donor screening tests for infectious diseases in blood and plasma. The Point of Care unit delivers rapid-testing instruments for use across various care settings, while the Molecular Diagnostics unit offers PCR thermocyclers, amplification systems, and sample-to-result instruments for syndromic infectious disease testing.
The company sells its products both through a direct sales force and via a distributor network, serving customers such as hospitals, clinical and reference laboratories, physician offices, urgent care clinics, universities, blood banks, and retail outlets. It also supplies products for over-the-counter and non-professional use. Geographically, QuidelOrtho operates across North America, Europe, the Middle East, Africa, China, Japan, Asia Pacific, and Latin America. The company was incorporated in 1979 and is classified within the Health Care Supplies sub-industry under the broader Health Care sector, operating in the in vitro diagnostics (IVD) market, which is a large and growing segment driven by demand for faster, decentralized testing and the ongoing need for infectious disease and chronic disease monitoring.
- COVID testing demand wind-down creates revenue and margin headwinds
- Savanna syndromic molecular platform placements accelerate across hospital labs
- Labs segment reagent revenue grows on expanding clinical chemistry installed base
| Net Income: -1.21b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA -1.81 > 1.0 |
| NWC/Revenue: 15.60% < 20% (prev 7.63%; Δ 7.97% < -1%) |
| CFO/TA 0.00 > 3% & CFO 6.60m > Net Income -1.21b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.43 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.2m) vs 12m ago 1.04% < -2% |
| Gross Margin: 44.96% > 18% (prev 46.94%; Δ -1.98% > 0.5%) |
| Asset Turnover: 43.96% > 50% (prev 42.79%; Δ 1.17% > 0%) |
| Interest Coverage Ratio: -5.35 > 6 (EBIT TTM -996.6m / Interest Expense TTM 186.4m) |
| A: 0.07 (Total Current Assets 1.38b - Total Current Liabilities 962.4m) / Total Assets 5.63b |
| B: -0.19 (Retained Earnings -1.09b / Total Assets 5.63b) |
| C: -0.16 (EBIT TTM -996.6m / Avg Total Assets 6.05b) |
| D: 0.49 (Book Value of Equity 1.85b / Total Liabilities 3.78b) |
| Altman-Z'' = -0.74 = B |
| DSRI: 1.16 (Receivables 486.7m/437.0m, Revenue 2.66b/2.76b) |
| GMI: 1.04 (GM 46.94% / 44.96%) |
| AQI: 0.87 (AQ_t 0.49 / AQ_t-1 0.56) |
| SGI: 0.96 (Revenue 2.66b / 2.76b) |
| TATA: -0.22 (NI -1.21b - CFO 6.60m) / TA 5.63b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 18.27 with a total of 1,248,803 shares traded. Over the past week, the price has changed by +0.11%, over one month by +35.33%, over three months by +31.91% and over the past year by -42.09%.
Current recommended Stop Loss: 16.20 (which is 11.3% or 1.5 ATR below the current price).
Quidel has received a consensus analysts rating of 3.88. Therefore, it is recommended to buy QDEL.
- StrongBuy: 3
- Buy: 2
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 20.5 | 12.2% |
P/E Forward = 7.2254
P/S = 0.4476
P/B = 0.6354
P/EG = 2.0638
Revenue TTM = 2.66b USD
EBIT TTM = -996.6m USD
EBITDA TTM = -548.8m USD
Long Term Debt = 2.46b USD (from longTermDebt, last quarter)
Short Term Debt = 259.5m USD (from shortTermDebt, last quarter)
Debt = 3.06b USD (from shortLongTermDebtTotal, last quarter) + Leases 186.7m
Net Debt = 2.92b USD (calculated: Debt 3.06b - CCE 140.4m)
Enterprise Value = 4.11b USD (1.19b + Debt 3.06b - CCE 140.4m)
Interest Coverage Ratio = -5.35 (Ebit TTM -996.6m / Interest Expense TTM 186.4m)
EV/FCF = -54.66x (Enterprise Value 4.11b / FCF TTM -75.2m)
FCF Yield = -1.83% (FCF TTM -75.2m / Enterprise Value 4.11b)
FCF Margin = -2.83% (FCF TTM -75.2m / Revenue TTM 2.66b)
Net Margin = -45.57% (Net Income TTM -1.21b / Revenue TTM 2.66b)
Gross Margin = 44.96% ((Revenue TTM 2.66b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = 42.56% (prev 44.28%)
Tobins Q-Ratio = 0.73 (Enterprise Value 4.11b / Total Assets 5.63b)
Interest Expense / Debt = 6.09% (Interest Expense 186.4m / Debt 3.06b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -787.3m (EBIT -996.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.43 (Total Current Assets 1.38b / Total Current Liabilities 962.4m)
Debt / Equity = 1.65 (Debt 3.06b / totalStockholderEquity, last quarter 1.85b)
Debt / EBITDA = -5.32 (negative EBITDA) (Net Debt 2.92b / EBITDA -548.8m)
Debt / FCF = -38.84 (negative FCF - burning cash) (Net Debt 2.92b / FCF TTM -75.2m)
Total Stockholder Equity = 2.15b (last 4 quarters mean from totalStockholderEquity)
RoA = -20.03% (Net Income -1.21b / Total Assets 5.63b)
RoE = -56.31% (Net Income TTM -1.21b / Total Stockholder Equity 2.15b)
RoCE = -21.62% (EBIT -996.6m / Capital Employed (Equity 2.15b + L.T.Debt 2.46b))
RoIC = -16.43% (negative operating profit) (NOPAT -787.3m / Invested Capital 4.79b)
WACC = 6.84% (E(1.19b)/V(4.25b) * Re(12.08%) + D(3.06b)/V(4.25b) * Rd(6.09%) * (1-Tc(0.21)))
Discount Rate = 12.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 76.41 | Cagr: 0.59%
[DCF] Fair Price = unknown (Cash Flow -75.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.61 | # QB: 0
Revenue Correlation: -93.52 | Revenue CAGR: -5.59% | SUE: -1.38 | # QB: -1
EPS current Quarter (2026-06-30): EPS=-0.04 | Chg30d=N/A | Revisions=-25% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.90 | Chg30d=+4.84% | Revisions=+50% | Analysts=3
EPS current Year (2026-12-31): EPS=1.86 | Chg30d=-3.33% | Revisions=-50% | GrowthEPS=-12.5% | GrowthRev=-0.7%
EPS next Year (2027-12-31): EPS=2.46 | Chg30d=-3.43% | Revisions=-57% | GrowthEPS=+32.5% | GrowthRev=+3.3%
[Analyst] Revisions Ratio: -36% (up=3, down=8)